Pharmaceutical

Lidocaine by MEDRx for Postherpetic Neuralgia: Likelihood of Approval

Lidocaine is under clinical development by MEDRx and currently in Pre-Registration for Postherpetic Neuralgia.

Dec 27, 2024 - 06:00
Lidocaine is under clinical development by MEDRx and currently in Pre-Registration for Postherpetic Neuralgia.
Read the original article

Tags:

Previous Article

StemVacs-V by Res Nova Bio for Metastatic Breast Cancer: Likelihood of Approval

Next Article

KGYY-15 by Op-T-Mune for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Appr...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca’s sBLA for LS-SCLC treatment gains FDA priority review

AstraZeneca’s sBLA for LS-SCLC treatment gains FDA prio...

Aug 17, 2024

STAT+: HHS leader on health and climate change talks health sector emissions and heat emergencies

STAT+: HHS leader on health and climate change talks he...

Oct 20, 2023

Enara Bio secures $32.5m for ‘Dark Antigen’ cancer therapies

Enara Bio secures $32.5m for ‘Dark Antigen’ cancer ther...

Oct 4, 2024